25 / 25
Conclusions
1. Long survivors with Anti-PD-1 (OS 3y 45-50%)
2. Complete Response with Anti-PD-1 (Stop treatment): 97% mantain CR.
3. Combo Ipi+Nivo: Benefit OS(descriptive analysis), Long survivors 63% 3-
years.
4. Complete Response Nivo plus Ipi: 92% patients free systemic treatment at 3-
years (48% Non-CR).
5. Pooled Analysis 3-y (CM 067-69): Patients alive and off study OS Combo 78%
(53% Nivo vs 32% Ipi). 69% Combo off treatment without received more lines
(41% Nivo vs 31% Ipi)
6. Selection treatment: Based clinical characterisitics, not selection by
biomarkers (PDL-1 weak biomarker)